Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Anavex Life Sciences Corp. before investing.

In this article, we go over a few key elements for understanding Anavex Life Sciences Corp.’s stock price such as:

• Anavex Life Sciences Corp.’s current stock price and volume
• Why Anavex Life Sciences Corp.’s stock price changed recently
• Upgrades and downgrades for AVXL from analysts
• AVXL’s stock price momentum as measured by its relative strength

About Anavex Life Sciences Corp. (AVXL)

Before we jump into Anavex Life Sciences Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Want to learn more about Anavex Life Sciences Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Anavex Life Sciences Corp..

Anavex Life Sciences Corp.’s Stock Price as of Market Close

As of January 16, 2026, 4:00 PM, CST, Anavex Life Sciences Corp.’s stock price was $5.010.

Anavex Life Sciences Corp. is up 3.3% from its previous closing price of $4.850.

During the last market session, Anavex Life Sciences Corp.’s stock traded between $4.729 and $5.190. Currently, there are approximately 85.89 million shares outstanding for Anavex Life Sciences Corp..

Anavex Life Sciences Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Anavex Life Sciences Corp. Stock Price History

Anavex Life Sciences Corp.’s (AVXL) price is currently up 40.73% so far this month.

During the month of January, Anavex Life Sciences Corp.’s stock price has reached a high of $5.190 and a low of $3.495.

Over the last year, Anavex Life Sciences Corp. has hit prices as high as $13.990 and as low as $2.860. Year to date, Anavex Life Sciences Corp.’s stock is up 40.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Anavex Life Sciences Corp. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 16, 2026, there were analysts who downgraded Anavex Life Sciences Corp.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Anavex Life Sciences Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Anavex Life Sciences Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Anavex Life Sciences Corp. (AVXL) by visiting AAII Stock Evaluator.

Relative Price Strength of Anavex Life Sciences Corp.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2026, Anavex Life Sciences Corp. has a weighted four-quarter relative price strength of -22.60%, which translates to a Momentum Score of 8 and is considered to be Very Weak.

Want to learn more about how Anavex Life Sciences Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Anavex Life Sciences Corp. Stock Price: Bottom Line

As of January 16, 2026, Anavex Life Sciences Corp.’s stock price is $5.010, which is up 3.3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Anavex Life Sciences Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.